By
There is no credible, publicly published single rejection rate for orthotics and prosthetics claims across the GCC. That is the most important starting point. Despite the size and maturity of Gulf health insurance markets, current public data does not appear to provide a unified regional percentage for denied or partially denied O&P claims in Saudi Arabia, the UAE, Qatar, Kuwait, Bahrain, and Oman. What does exist is a patchwork of complaint channels, insurer adjudication rules, and a small number of broader claims studies that strongly suggest reimbursement friction is real, even if the O&P-specific denial rate remains opaque.
That lack of transparency matters because orthotics and prosthetics occupy an awkward space in many insurance systems. O&P services are not always treated like straightforward physician visits or routine pharmacy claims. Instead, they often sit at the intersection of medical necessity review, prior authorization, network limitations, benefit schedule exclusions, policy ceilings, coding rules, and documentation scrutiny. In practical terms, that means claims may be rejected not only because a device is uncovered, but because the indication, wording, paperwork, provider status, or pre-approval pathway does not align cleanly with the insurer’s rules. This is an inference from the structure of GCC complaint and adjudication systems, especially where insurers explicitly publish detailed coverage rules and resubmission processes.
Saudi Arabia is the clearest example of a large market where complaints are visible but O&P-specific denial data is not. The Council of Health Insurance says complaints against insurers can be filed electronically, and older but still relevant CHI reporting showed that most insurance complaints were directed against insurance companies and often related to beneficiaries being unable to obtain basic available benefits. More recently, CHI’s provider classification materials explicitly require organizations to classify, track, and continuously reduce rejected claims, which shows that claim rejection is a recognized quality and compliance issue in the Saudi insurance ecosystem. But none of these public materials break out orthotics and prosthetics as a separate rejection-rate category.
In the UAE, the picture is similar. Daman publicly states that members can check coverage against their Schedule of Benefits, consult published adjudication rules, and resubmit claims if they were rejected or partially approved. Dubai’s health regulator also maintains a unified complaint system for insured members to escalate disputes against insurers. These are useful governance tools, but they do not answer the question many O&P providers actually care about: how often are prosthetic and orthotic claims denied, reduced, or delayed? Public-facing materials show the dispute architecture exists, not the denial-rate transparency many providers would want.
Qatar appears even less insurance-rejection-driven in public O&P visibility, because much of its prosthetic and orthotic care is prominently represented through the public rehabilitation system at Hamad Medical Corporation and Qatar Rehabilitation Institute. Public pages highlight dedicated prosthetics and orthotics services and broader rehabilitation infrastructure, but they do not provide clear insurer denial metrics for private reimbursement. In other words, Qatar clearly has organized O&P service delivery, but not a public dataset that lets us quantify orthotics and prosthetics insurance rejection in the way a private-market analyst might prefer.
The best published GCC claims-denial number I found comes from Kuwait, but it is not O&P-specific. A 2025 peer-reviewed analysis of Kuwait’s National Health Insurance for Retirees (AFYA) examined 4.44 million claims from 2016 to 2023 and found an overall rejection rate of 3.85%. The study is valuable because it gives one of the rare quantified GCC denial baselines from a major health insurance program. But it covers claims broadly across medical, dental, and pharmaceutical categories, not orthotics and prosthetics specifically. So it can be used only as a directional regional reference point, not as an O&P denial rate.
That Kuwait study also helps explain why O&P claims may be vulnerable. It found that rejection patterns vary by service category, claimed amount, provider type, and claim year. Orthotics and prosthetics claims are often relatively high-value compared with routine outpatient consultations, and they may involve more documentation, more review, and more opportunities for insurers to question medical necessity, coding, or benefit eligibility. The study did not analyze O&P separately, but its findings strongly support the idea that specialized, higher-complexity claims can face different rejection dynamics than simple volume claims. That is an inference based on the published determinants of rejection in AFYA.
So what is the likely real-world situation across the GCC? The available evidence suggests that O&P denial pressure is probably driven less by a single regional rejection percentage and more by five recurring failure points: lack of prior approval, out-of-network treatment, policy exclusions or ceilings, insufficient clinical documentation, and billing/coding errors. UAE insurer guidance publicly references coverage schedules, adjudication criteria, and rejected-claim resubmission processes, while Saudi and UAE complaint pathways both emphasize documentation. These are classic indicators of a claims environment where O&P cases can be slowed or denied even when they are clinically justified.
For O&P providers across the Gulf, that has commercial consequences. A prosthesis or custom orthosis is not just a product sale; it is usually a multi-step reimbursed episode involving consultation, assessment, sometimes imaging or physician referral, fabrication, fitting, follow-up, and sometimes physiotherapy or gait training. The more complex the pathway, the more denial risk migrates from simple coverage questions into process questions. That helps explain why the absence of a published GCC-wide O&P rejection rate is itself a market problem: providers are forced to navigate reimbursement with too little benchmarking data. This is an inference, but it is grounded in the documented complexity of GCC claims governance and the lack of transparent O&P-specific reporting.
For IMEA CPO readers, the biggest lesson is not “the rejection rate is X.” It is that the GCC still lacks the kind of reimbursement transparency that would let providers, manufacturers, and policymakers improve O&P access systematically. Saudi Arabia, the UAE, and Oman all provide formal complaint mechanisms or adjudication structures. Kuwait now offers a useful broader claims study. But none of this yet adds up to a region-wide prosthetics and orthotics rejection dashboard. Until that changes, clinics and distributors will need to manage denial risk operationally rather than statistically.
That means practical discipline matters. Gulf O&P providers are likely to perform better when they tighten pre-authorization workflows, benefit verification, physician documentation, coding accuracy, and insurer-specific submission rules before fabrication begins. In markets where a denied high-value claim can materially affect cash flow, reimbursement operations become just as important as clinical operations. That final point is an inference, but it is hard to avoid given the documented claims frameworks and the absence of clean public rejection-rate data for O&P.
Bottom line
The GCC does not currently offer a reliable published regional rejection rate for orthotics and prosthetics claims. The closest quantified Gulf benchmark I found is Kuwait’s broader AFYA insurance rejection rate of 3.85%, but that is not O&P-specific. Across Saudi Arabia, the UAE, Qatar, Oman, Bahrain, and Kuwait, the stronger conclusion is that O&P reimbursement friction clearly exists, but the data remains fragmented, insurer-specific, and largely non-transparent. For the sector, that makes reimbursement strategy a competitive advantage and better claims reporting a regional priority.
